SEC62 and ovarian cancer: To address the role of SEC62 as a possible prognostic marker in patients with ovarian neoplasia, 171 patients with primary ovarian cancer and borderline tumors of the ovary, who were treated at the Department of Gynecology and Obstetrics, Saarland University Hospital, Homburg, Germany, were assessed for eligibility.